Compare Western Alliance Bancorporation (WAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs Zoetis Inc — how do they compare? Western Alliance Bancorporation trades at $79.8 (market cap $8.84B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3.6× Western Alliance Bancorporation's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| WAL | ZTS | |
|---|---|---|
Market Cap | $8.84B | $31.95B |
Sector | Financials | Health |
52-Week High | $96.08 | $156.76 |
52-Week Low | $66.70 | $71.91 |
Dividend Yield | 2.07% | 2.78% |
Enterprise Value | — | $39.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.43 and net income margin of 25.63%, supported by consistent quarterly earnings outperformance. Recent news highlights Q2 2026 earnings miss but positive corporate recognition and leadership appointments.
Outlook remains positive with analyst consensus price target of $90.67 suggesting 12% upside. Risks include negative operating cash flow and high interest expenses. The bullish analyst sentiment (79% buy ratings) contrasts with technical bearishness, indicating potential value opportunity if fundamentals hold.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
